ALDX - NASDAQ
Aldeyra Therapeutics, Inc.
$1.86
+0.71%Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
At a Glance
Live SnapshotAldeyra Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Aldeyra Therapeutics, Inc. Cash Flow Statement
ALDX • NASDAQ
| Aldeyra Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-33,846.7B | -55.9M | -37.5M | -62M | -57.8M | -37.6M | -60.8M | -38.9M | -22.3M | -18.7M | -12.1M | -5.2M | 13.1M | -23.1M | -2.4M | |
-897.6B | 249.6K | 262.8K | 258.7K | 264.2K | 56.2K | 96.3K | 71K | 37.8K | 35.8K | 18.8K | 1.1K | 0.0 | 3.7K | 1.6K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -479.3K | -1.3M | -237.5K | 129.2K | 266.1K | 0.0 | -2.3M | 0.0 | 134.5K | 0.0 | |
6,091.4B | 8M | 5.8M | 8.3M | 7.1M | 7.1M | 8.1M | 4.1M | 2.7M | 2.8M | 2.2M | 2M | 1.7M | 84.4K | 49.6K | |
-4,692.9B | -1.5M | 339.7K | 283.9K | 409.5K | 2.2M | 6.2M | 59.3K | 20.3K | 27.3K | 35.8K | 150.9K | -16.7M | 22M | 0.0 | |
-5.2M | 5.9M | 861.2K | -3.4M | 7.4M | -8.8M | 2.7M | 5M | 215.5K | 463K | 536.8K | 549.8K | 259.6K | 91.7K | -65.9K | |
-33,345.7B | -43.2M | -30.3M | -56.6M | -42.6M | -37.5M | -45M | -29.9M | -19.2M | -15.1M | -9.3M | -4.8M | -1.7M | -778K | -2.4M | |
INVESTING ACTIVITIES | |||||||||||||||
(0.0) | (0.0) | (0.0) | -16.3K | -7.8K | (0.0) | -9.5K | -263K | -24.8K | -11.8K | -86.1K | -14.1K | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | (16.3K) | (0.0) | (0.0) | (609.5K) | (263B) | (24.8B) | (11.8K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-40,263.7B | -96.9M | (0.0) | -92.9M | (0.0) | -5.8M | -57.8M | -59.7M | -35.1M | -16M | -13M | (0.0) | (0.0) | (0.0) | (0.0) | |
88,000B | 52M | 30M | 63M | 0.0 | 34.8M | 75.6M | 36.7M | 24.9M | 15.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -16.3K | 0.0 | 0.0 | 0.0 | -263B | -24.8B | -11.8K | -13M | -14.1K | 0.0 | 0.0 | 0.0 | |
(47,736.3B) | -44.9M | (30M) | -30M | -7.8K | (29M) | (18.5M) | -23.3M | -10.2M | -225.2K | -13M | -14.1K | (0.0) | (0.0) | (0.0) | |
FINANCING ACTIVITIES | |||||||||||||||
1.1M | 121.1K | 305.2K | 1.2M | 189.8M | 40.7M | 7.9M | 81.8M | 37.6M | 12.7M | 28.5M | 10.1M | 7.1K | 0.0 | 0.0 | |
0.0 | -292.5K | -1M | 0.0 | 0.0 | 0.0 | 14.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1M | 500K | 0.0 | |
1,123.6B | 0.0 | -533K | 0.0 | 4.7M | 1.2M | 1.2M | -1.4M | -165.9K | 0.0 | -36.2K | 0.0 | -78.1K | 0.0 | 0.0 | |
1,123.6B | -171.4K | -1.3M | 1.2M | 194.5M | 41.9M | 23.6M | 80.5M | 37.4M | 12.7M | 28.5M | 10.1M | 3.7M | 1.8M | 0.0 | |
CASH FLOW SUMMARY | |||||||||||||||
15,514.2B | -88.3M | -1.6M | -85.4M | 151.9M | 33.4M | -2.9M | 27.3M | 8M | -2.6M | 6.1M | 5.3M | 2M | 972.7K | -2.4M | |
54,527.1B | 142.8M | 144.4M | 229.8M | 77.9M | 44.4M | 47.4M | 20M | 12M | 14.6M | 8.5M | 3.3M | 1.2M | 251K | 2.6M | |
70,041.3B | 54.5M | 142.8M | 144.4M | 229.8M | 77.9M | 44.4M | 47.4M | 20M | 12M | 14.6M | 8.5M | 3.3M | 1.2M | 251K | |
-33,345.7B | -43.2M | -30.3M | -56.7M | -42.6M | -37.5M | -45M | -30.1M | -19.2M | -15.2M | -9.4M | -4.8M | -1.7M | -778K | -2.4M |
SEC Filings
ALDX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | May 01, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 27, 2026 | June 10, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 20, 2026 | April 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 01, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 31, 2025 | December 23, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 16, 2025 | December 15, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 |
Related Guides
Continue your ALDX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.